» Articles » PMID: 38863020

Deciphering the Performance of Macrophages in Tumour Microenvironment: a Call for Precision Immunotherapy

Overview
Journal J Hematol Oncol
Publisher Biomed Central
Specialties Hematology
Oncology
Date 2024 Jun 11
PMID 38863020
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophages infiltrating tumour tissues or residing in the microenvironment of solid tumours are known as tumour-associated macrophages (TAMs). These specialized immune cells play crucial roles in tumour growth, angiogenesis, immune regulation, metastasis, and chemoresistance. TAMs encompass various subpopulations, primarily classified into M1 and M2 subtypes based on their differentiation and activities. M1 macrophages, characterized by a pro-inflammatory phenotype, exert anti-tumoural effects, while M2 macrophages, with an anti-inflammatory phenotype, function as protumoural regulators. These highly versatile cells respond to stimuli from tumour cells and other constituents within the tumour microenvironment (TME), such as growth factors, cytokines, chemokines, and enzymes. These stimuli induce their polarization towards one phenotype or another, leading to complex interactions with TME components and influencing both pro-tumour and anti-tumour processes.This review comprehensively and deeply covers the literature on macrophages, their origin and function as well as the intricate interplay between macrophages and the TME, influencing the dual nature of TAMs in promoting both pro- and anti-tumour processes. Moreover, the review delves into the primary pathways implicated in macrophage polarization, examining the diverse stimuli that regulate this process. These stimuli play a crucial role in shaping the phenotype and functions of macrophages. In addition, the advantages and limitations of current macrophage based clinical interventions are reviewed, including enhancing TAM phagocytosis, inducing TAM exhaustion, inhibiting TAM recruitment, and polarizing TAMs towards an M1-like phenotype. In conclusion, while the treatment strategies targeting macrophages in precision medicine show promise, overcoming several obstacles is still necessary to achieve an accessible and efficient immunotherapy.

Citing Articles

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.


Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions.

Xuan Z, Hu H, Xu J, Ling X, Zhang L, Li W J Cell Mol Med. 2025; 29(5):e70460.

PMID: 40074697 PMC: 11903196. DOI: 10.1111/jcmm.70460.


Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.


Overexpression of ornithine decarboxylase 1 mediates the immune-deserted microenvironment and poor prognosis in diffuse large B-cell lymphoma.

Liang X, Guo J, Wang X, Luo B, Fu R, Chen H J Natl Cancer Cent. 2025; 5(1):57-74.

PMID: 40040873 PMC: 11873660. DOI: 10.1016/j.jncc.2024.10.001.


Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.

Jin P, Bai X IBRO Neurosci Rep. 2025; 18:323-337.

PMID: 40034544 PMC: 11872630. DOI: 10.1016/j.ibneur.2025.01.015.


References
1.
Jordakieva G, Bianchini R, Reichhold D, Piehslinger J, Groschopf A, Jensen S . IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. Oncoimmunology. 2021; 10(1):1880687. PMC: 7889146. DOI: 10.1080/2162402X.2021.1880687. View

2.
Jia N, Wu H, Duan J, Wei C, Wang K, Zhang Y . Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo. J Vis Exp. 2019; (144). DOI: 10.3791/58660. View

3.
Dixit A, Sarver A, Zettervall J, Huang H, Zheng K, Brekken R . Targeting TNF-α-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling. JCI Insight. 2022; 7(22). PMC: 9746819. DOI: 10.1172/jci.insight.153242. View

4.
Yang D, Yang L, Cai J, Hu X, Li H, Zhang X . A sweet spot for macrophages: Focusing on polarization. Pharmacol Res. 2021; 167:105576. DOI: 10.1016/j.phrs.2021.105576. View

5.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View